MOTS-c in Orlando
MOTS-c is a 16-amino-acid peptide with an unusual origin. DNA encodes most peptides in the body in the cell nucleus. MOTS-c is encoded by mitochondrial DNA, the separate small genome inside the structures that produce cellular energy.
There is no FDA approval for MOTS-c and no indication it is approved for treatment. FDA’s 2026 evaluation found no published studies in which compounded or noncompounded drug products containing MOTS-c free base or MOTS-c acetate were administered to humans.
How It Works
Animal and cell-model research has examined MOTS-c in relation to a cellular energy-sensing pathway involved in how tissues respond to exercise and metabolic stress. Observational research has reported associations between circulating or tissue MOTS-c and age or exercise. These associations do not establish that injecting MOTS-c reproduces the effects of exercise or reverses age-related change.
An association between a molecule and a healthy state does not mean supplying the molecule reproduces that state. That step has not been tested in people.
Potential Benefits
Interest in MOTS-c centers on:
Metabolic function and insulin sensitivity
Exercise capacity and endurance
Body composition
Age-related metabolic decline
These interests come primarily from animal and cell research, with observational human biology studies that do not establish treatment benefit. Because clinical administration data are unavailable or extremely limited, the benefits and risks of using MOTS-c as a drug in people cannot be established.
Who May Be an Appropriate Candidate
Metabolic concerns warrant a workup before they warrant a compound. Insulin resistance, thyroid function, hormone levels, sleep apnea, and medication effects are measurable, common, and treatable, and addressing them produces results that a peptide with no human data cannot promise.
MOTS-c should generally be avoided or require specialist review because safety data are unavailable, especially for:
Pregnant or breastfeeding women
Active cancer, previous cancer, or unexplained masses
Type 1 diabetes or unstable blood sugar
Significant kidney or liver disease
How It Is Administered
Route
MOTS-c has been proposed for subcutaneous injection in compounding materials, but no FDA-approved route exists. Other marketed routes should not be assumed safe or effective.
Who Does It
Administered by you at home, following a session with our team.
How Often It May Be Used
Short defined cycles rather than continuous use, often several times per week rather than daily. No established dosing research supports any particular schedule, so your provider will specify a course and a point to evaluate.
Safety Considerations
MOTS-c should not be marketed or understood as a treatment for metabolism, weight loss, exercise performance, longevity, or mitochondrial disease. No human clinical trials establish MOTS-c as safe or effective for these uses.
The FDA’s position is worth stating precisely, because it differs from its position on better-studied peptides:
No human exposure data has been identified for MOTS-c drug products
Available information is insufficient to assess safety
Immune response, impurities, and ingredient characterization remain open questions
MOTS-c was also among the substances an FDA advisory committee voted in July 2026 to allow in pharmacy compounding. That vote is advisory, and no final determination has been issued, so availability may change.
Because there is no human safety record, report anything unexpected without waiting to see whether it passes.
Talk With Our Clinical Team
We will lay out what is known, which here is less than most patients expect, and let you decide with that in front of you. We will not prescribe a peptide without current bloodwork on record. It tells us what to rule out first.
The discovery consultation costs you nothing, and you may stop there.